China National Accord Medicines Corporation Ltd. (SHE: 000028)
China
· Delayed Price · Currency is CNY 27.95
-1.26 (-4.31%)
Oct 11, 2024, 3:04 PM CST
China National Accord Medicines Corporation Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 74,211 | 74,844 | 72,701 | 67,648 | 59,130 | 52,403 | Upgrade
|
| Other Revenue | 664.49 | 633.35 | 742.57 | 710.01 | 519.9 | 383.75 | Upgrade
|
| Revenue | 74,876 | 75,477 | 73,443 | 68,358 | 59,649 | 52,787 | Upgrade
|
| Revenue Growth (YoY) | -1.09% | 2.77% | 7.44% | 14.60% | 13.00% | 22.41% | Upgrade
|
| Cost of Revenue | 66,183 | 66,471 | 64,561 | 60,372 | 52,623 | 46,916 | Upgrade
|
| Gross Profit | 8,693 | 9,006 | 8,883 | 7,986 | 7,026 | 5,870 | Upgrade
|
| Selling, General & Admin | 6,422 | 6,404 | 6,374 | 5,772 | 4,925 | 4,015 | Upgrade
|
| Research & Development | 27.75 | 26.82 | 9.07 | - | - | - | Upgrade
|
| Other Operating Expenses | 177.41 | 152.33 | 180.1 | 139.09 | 141.8 | 136.65 | Upgrade
|
| Operating Expenses | 6,679 | 6,659 | 6,585 | 5,955 | 5,088 | 4,157 | Upgrade
|
| Operating Income | 2,013 | 2,347 | 2,298 | 2,031 | 1,938 | 1,714 | Upgrade
|
| Interest Expense | -271.22 | -248.38 | -261.91 | -288.04 | -258.19 | -276.49 | Upgrade
|
| Interest & Investment Income | 343.91 | 314.58 | 212.07 | 366.68 | 420.41 | 386.05 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.69 | 2.95 | -0.44 | 0.41 | -0.05 | -0.39 | Upgrade
|
| Other Non Operating Income (Expenses) | -36.84 | -36.66 | -1.89 | -4.87 | -0.61 | -37.73 | Upgrade
|
| EBT Excluding Unusual Items | 2,048 | 2,380 | 2,245 | 2,105 | 2,100 | 1,785 | Upgrade
|
| Impairment of Goodwill | - | - | -38.98 | -162.69 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -29.44 | -15.16 | 28.87 | - | - | -1.86 | Upgrade
|
| Gain (Loss) on Sale of Assets | 41.3 | 45.31 | 8.31 | 4.25 | 6.79 | 2.55 | Upgrade
|
| Asset Writedown | -1.01 | -0.9 | -18.87 | -75.55 | -1.31 | - | Upgrade
|
| Legal Settlements | -3.25 | -3.25 | -0.05 | -0.55 | -16.51 | -0.24 | Upgrade
|
| Other Unusual Items | 84.38 | 67.53 | 86.36 | 104.09 | 68.43 | 65.67 | Upgrade
|
| Pretax Income | 2,140 | 2,473 | 2,311 | 1,975 | 2,157 | 1,851 | Upgrade
|
| Income Tax Expense | 440.4 | 514.74 | 539.33 | 447.21 | 435.94 | 371.3 | Upgrade
|
| Earnings From Continuing Operations | 1,699 | 1,958 | 1,772 | 1,528 | 1,721 | 1,480 | Upgrade
|
| Minority Interest in Earnings | -186.64 | -359.23 | -285.03 | -191.21 | -319.4 | -212.23 | Upgrade
|
| Net Income | 1,512 | 1,599 | 1,487 | 1,336 | 1,402 | 1,268 | Upgrade
|
| Net Income to Common | 1,512 | 1,599 | 1,487 | 1,336 | 1,402 | 1,268 | Upgrade
|
| Net Income Growth | -7.93% | 7.57% | 11.24% | -4.67% | 10.57% | 4.72% | Upgrade
|
| Shares Outstanding (Basic) | 555 | 557 | 557 | 557 | 557 | 557 | Upgrade
|
| Shares Outstanding (Diluted) | 555 | 557 | 557 | 557 | 557 | 557 | Upgrade
|
| Shares Change (YoY) | -0.21% | - | -0.00% | - | - | - | Upgrade
|
| EPS (Basic) | 2.72 | 2.87 | 2.67 | 2.40 | 2.52 | 2.28 | Upgrade
|
| EPS (Diluted) | 2.72 | 2.87 | 2.67 | 2.40 | 2.52 | 2.28 | Upgrade
|
| EPS Growth | -7.81% | 7.49% | 11.25% | -4.59% | 10.47% | 4.67% | Upgrade
|
| Free Cash Flow | 2,073 | 2,615 | 2,238 | 1,285 | 1,209 | 1,761 | Upgrade
|
| Free Cash Flow Per Share | 3.73 | 4.70 | 4.02 | 2.31 | 2.17 | 3.16 | Upgrade
|
| Dividend Per Share | 0.680 | 0.680 | 0.615 | 0.462 | 0.615 | 0.462 | Upgrade
|
| Dividend Growth | 10.50% | 10.50% | 33.35% | -25.01% | 33.35% | 49.98% | Upgrade
|
| Gross Margin | 11.61% | 11.93% | 12.09% | 11.68% | 11.78% | 11.12% | Upgrade
|
| Operating Margin | 2.69% | 3.11% | 3.13% | 2.97% | 3.25% | 3.25% | Upgrade
|
| Profit Margin | 2.02% | 2.12% | 2.02% | 1.96% | 2.35% | 2.40% | Upgrade
|
| Free Cash Flow Margin | 2.77% | 3.46% | 3.05% | 1.88% | 2.03% | 3.34% | Upgrade
|
| EBITDA | 2,216 | 2,566 | 2,542 | 2,239 | 2,106 | 1,846 | Upgrade
|
| EBITDA Margin | 2.96% | 3.40% | 3.46% | 3.27% | 3.53% | 3.50% | Upgrade
|
| D&A For EBITDA | 202.32 | 218.57 | 244.32 | 207.45 | 167.71 | 131.63 | Upgrade
|
| EBIT | 2,013 | 2,347 | 2,298 | 2,031 | 1,938 | 1,714 | Upgrade
|
| EBIT Margin | 2.69% | 3.11% | 3.13% | 2.97% | 3.25% | 3.25% | Upgrade
|
| Effective Tax Rate | 20.58% | 20.81% | 23.34% | 22.65% | 20.21% | 20.05% | Upgrade
|
| Advertising Expenses | - | 28.58 | 46.67 | 44.12 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.